Physician profile
Vu Nguyen
NPI 1285627745
$4,117.34
in general payments reported to CMS, 2019-2025
26 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $507 · 2021: $646 · 2022: $712 · 2023: $830 · 2024: $456 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,062.15 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $597.79 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $584.02 | 2021-2025 | |
| Musculoskeletal Transplant Foundation INC. | $309.15 | 2019-2023 | |
| Novo Nordisk INC | $271.21 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.02 | 2019-2022 | |
| Allergan, INC. | $186.27 | 2019-2020 | |
| Pfizer INC. | $137.29 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $86.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $81.64 | 2022 | |
| Amarin Pharma, INC. | $76.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.00 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $65.19 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.33 | 2022 | |
| Dexcom, INC. | $47.50 | 2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.67 | 2021 | |
| Gilead Sciences, INC. | $39.48 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.22 | 2022-2025 | Zoryve |
| Horizon Therapeutics Plc | $27.87 | 2021-2022 | |
| Celgene Corporation | $25.84 | 2019 | |
| Esperion Therapeutics, INC. | $24.42 | 2020 | |
| Lundbeck LLC | $24.00 | 2022 | |
| Genentech USA, INC. | $22.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.44 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.27 | 2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.